Asston Pharmaceuticals Ltd
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]
- Market Cap ₹ 57.2 Cr.
- Current Price ₹ 67.2
- High / Low ₹ 126 / 61.0
- Stock P/E 14.8
- Book Value ₹ 45.6
- Dividend Yield 0.00 %
- ROCE 16.8 %
- ROE 15.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.6.12 Cr.
- Company has high debtors of 524 days.
- Working capital days have increased from 259 days to 434 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 9.60 | 6.54 | 16.03 | 25.04 | 25.47 | |
| 9.96 | 5.02 | 12.21 | 19.60 | 26.04 | |
| Operating Profit | -0.36 | 1.52 | 3.82 | 5.44 | -0.57 |
| OPM % | -3.75% | 23.24% | 23.83% | 21.73% | -2.24% |
| 0.96 | 0.65 | 0.25 | 0.57 | 6.12 | |
| Interest | 0.43 | 0.72 | 0.76 | 0.95 | 0.63 |
| Depreciation | 0.01 | 0.04 | 0.06 | 0.04 | 0.32 |
| Profit before tax | 0.16 | 1.41 | 3.25 | 5.02 | 4.60 |
| Tax % | 31.25% | 25.53% | 25.23% | 23.11% | 15.87% |
| 0.11 | 1.06 | 2.43 | 3.85 | 3.87 | |
| EPS in Rs | 1.57 | 15.14 | 31.00 | 6.14 | 4.55 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 57% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 54% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 26% |
| Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 0.78 | 6.27 | 8.51 |
| Reserves | 0.23 | 1.29 | 6.40 | 4.76 | 30.35 |
| 3.31 | 5.24 | 6.82 | 7.25 | 5.11 | |
| 5.25 | 6.46 | 6.70 | 9.84 | 7.68 | |
| Total Liabilities | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
| 0.92 | 1.13 | 0.97 | 0.96 | 10.69 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| 8.57 | 12.56 | 19.73 | 27.16 | 40.96 | |
| Total Assets | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -1.19 | -0.32 | -3.97 | -0.03 | -10.18 | |
| -0.00 | -0.91 | -0.01 | 0.73 | -9.91 | |
| 1.29 | 1.21 | 3.86 | -0.51 | 21.18 | |
| Net Cash Flow | 0.10 | -0.01 | -0.12 | 0.19 | 1.09 |
| Free Cash Flow | -1.19 | -0.57 | -3.98 | -0.06 | -20.24 |
| CFO/OP | 322% | -20% | -92% | -0% | 1,368% |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 243.33 | 480.53 | 380.71 | 357.86 | 524.07 |
| Inventory Days | 27.24 | 204.29 | 53.91 | 18.59 | 16.14 |
| Days Payable | 246.78 | 754.51 | 217.50 | 154.11 | 120.76 |
| Cash Conversion Cycle | 23.79 | -69.70 | 217.12 | 222.34 | 419.45 |
| Working Capital Days | -12.17 | 43.53 | 162.80 | 178.86 | 434.22 |
| ROCE % | 37.14% | 37.78% | 36.62% | 16.80% |
Insights
In beta| Mar 2023 | Mar 2024 | May 2025 | |
|---|---|---|---|
| Export Revenue (% of Total Sales) % |
|
||
| Pharmaceuticals Sales (% of Total Sales) % |
|||
| Sierra Leone Revenue (% of Total Sales) % |
|||
| Top 5 Customer Concentration (% of Revenue) % |
|||
| Total Production Volume MT |
|||
| Number of Registered Product Brands count |
|||
| Order Book USD |
|||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 10 Jul
- Notice Of Second Extraordinary General Meeting For F.Y. 2026-27 Scheduled To Be Held On 31St July, 2026 At 12:30 PM 9 Jul
-
Announcement under Regulation 30 (LODR)-Meeting Updates
2 Jul - Board approved preferential issue of up to 24,10,431 shares raising ₹27.72 crore; EGM on 31 July 2026.
-
Announcement Regarding Extraordinary General Meeting Of The Company.
2 Jul - Board approved preferential issue of 24,10,431 shares at ₹115, raising up to ₹27.72 crore; EGM on 31 July 2026.
Business Overview:[1]
APL offers pharmaceutical products in the form of Tablet, Capsules, Syrup, Sachet and Injection (LVP and SVP). The company has WHO GMP approved manufacturing units for manufacturing
the entire products range and also has
a tie up with a NABL Accredited Laboratory.